The structures in question are known as artery tertiary lymphoid organs, or ATLOs. Unlike the classical lymph nodes and spleen, which develop during embryogenesis and serve the entire body, tertiary lymphoid organs arise postnatally in response to chronic inflammation at affected tissues. In atherosclerosis, they form in the adventitia, the outermost layer of the arterial wall, adjacent to plaques rich in immune cells. Previous work had established that these structures contain germinal centers, the specialized microenvironments where B cells proliferate, mutate their antibody genes, and undergo selection for increasingly potent antigen binding. What remained unknown was what these germinal centers were actually targeting, and whether the antibodies they produced mattered for disease.

To answer those questions, the research team, led by Zihao Zhang, Yue Zhang, Shu Ran, Ying Wang and colleagues, combined single-cell transcriptomic profiling with B cell receptor sequencing of germinal center B cells harvested from artery tertiary lymphoid organs. Single-cell transcriptomics allows researchers to capture the complete gene expression program of individual cells, revealing their identity, activation state, and developmental trajectory. B cell receptor sequencing, meanwhile, reads out the rearranged antibody genes carried by each B cell, providing a molecular fingerprint of the antigen-binding receptor that defines the cell’s specificity. By layering these two datasets on top of one another, the investigators could reconstruct, at unprecedented resolution, the population of B cells being educated within the arterial wall itself.

The analysis revealed a clonally expanded population of autoreactive B cells within the ATLO germinal centers, indicating that these cells had undergone the canonical process of somatic hypermutation and antigen-driven selection that normally refines antibody responses during infection or vaccination. From this population, the team cloned a monoclonal antibody, designated A6, and demonstrated that it binds with high affinity to histone 2B, or H2B, one of the core histone proteins around which DNA is wrapped in every cell nucleus. Histones are potent immunological stimuli, well known to activate innate immune pathways, but the identification of a germinal center-derived, high-affinity antibody specific for H2B within the artery wall was unexpected and mechanistically significant.

The pathogenic relevance of the finding was established through two complementary lines of experimentation. First, the researchers tested H2B vaccination: when animals were immunized with histone 2B, the resulting immune response markedly accelerated the progression of atherosclerosis, confirming that a targeted anti-H2B response is sufficient to worsen disease. Second, and more directly, the team performed adoptive transfer of the anti-H2B A6 monoclonal antibody itself. Simply delivering the purified antibody into circulation was enough to significantly speed plaque development, demonstrating that the antibody is not merely a marker of the disease process but an active driver of it.

These results carry substantial mechanistic weight because they close a causal loop. Earlier studies had documented that tertiary lymphoid organs appear in the arterial adventitia as atherosclerosis advances, and that their germinal centers become more prominent with disease severity. But correlation is not causation, and it remained possible that the local immune structures were protective, attempting to contain plaque inflammation, or merely incidental. By identifying a specific autoantibody-autoantigen pair encoded within these structures and showing that the antibody accelerates disease when transferred, the study establishes that ATLOs are not passive observers but productive factories of pathogenic humoral immunity.

The technical achievement underlying the discovery deserves emphasis. Germinal center B cells are notoriously difficult to study because they are short-lived, rapidly dividing, and spatially restricted within organized lymphoid tissue. Extracting them from the arterial wall, dissociating the tissue into single cells while preserving RNA quality, and obtaining paired heavy- and light-chain B cell receptor sequences from each cell requires meticulous single-cell handling. The successful cloning of a functional monoclonal antibody from this dataset, one that retains its specificity and pathogenic activity when expressed recombinantly, validates the entire pipeline and opens the door to systematically cataloging the full repertoire of antigens targeted within atherosclerotic ATLOs.

The identification of H2B as the target antigen also connects atherosclerosis to a broader theme in autoimmunity. Anti-histone antibodies are hallmarks of several systemic autoimmune diseases, most notably drug-induced lupus, where they bind nuclear components released by dying cells. In atherosclerotic plaques, cell death is abundant: foam cells undergo apoptosis, necrotic cores accumulate, and nuclear debris is released into the plaque microenvironment. It is plausible that this ongoing cell death provides a continuous supply of histone antigen, which drains to the adjacent adventitial lymphoid structures and drives the affinity maturation of autoreactive B cells. The new findings suggest that atherosclerosis may therefore share fundamental immunological machinery with classical autoimmune diseases, a concept that reframes how the field thinks about cardiovascular inflammation.

Therapeutically, the work suggests several possible avenues, though the researchers are careful to note that translation from experimental models to human patients will require further validation. If comparable anti-H2B responses are confirmed in human atherosclerotic arteries, the autoantibody could serve as a biomarker for identifying patients whose disease is driven by autoreactive immunity. More ambitiously, the pathways that organize and sustain artery tertiary lymphoid organs, including the lymphotoxin and chemokine networks that recruit and retain lymphocytes in the vessel wall, could become targets for interventions designed to quiet local antibody production without globally suppressing protective immunity. Given that atherosclerosis remains the leading cause of death worldwide despite aggressive lipid-lowering therapy, any mechanism that explains residual cardiovascular risk in patients is of enormous clinical interest.

The study also raises fundamental questions about how immune tolerance breaks down inside the artery. Germinal centers normally enforce stringent selection against self-reactive B cells, yet the ATLO germinal centers clearly nurtured a high-affinity autoreactive clone to maturity. Understanding why the arterial environment licenses this breach, whether through the character of the antigens presented, the cytokine milieu, or the absence of regulatory cell networks found in conventional lymphoid tissue, may reveal general principles applicable to other chronic inflammatory diseases in which tertiary lymphoid structures arise, from rheumatoid arthritis to organ transplant rejection. For now, the demonstration that a single cloned antibody targeting a nuclear protein can measurably accelerate the arterial disease that kills more people than any other stands as a vivid reminder that the immune system, in the wrong context, can be as dangerous as any traditional risk factor.

The adventitia, where these lymphoid structures take root, has long been treated as a largely passive scaffold of collagen, vasa vasorum, and resident fibroblasts. The demonstration that it can host affinity-matured humoral responses repositions this outer arterial layer as an immunologically active compartment. It also helps explain earlier observations that immune-cell clusters in the adventitia expand in parallel with plaque burden and that lymphatic vessels draining the arterial wall become more prominent as disease advances, providing a plausible route by which plaque-derived antigens reach the local immune structures.

Histone 2B belongs to a family of proteins that are normally sequestered inside the nucleus, where they package DNA into nucleosomes. When cells die, particularly through the inflammatory forms of cell death common in plaques, histones can escape into the extracellular space, where they act as damage-associated molecular patterns that stimulate innate receptors. The new work shows that this same nuclear material can also serve as a target for affinity-matured adaptive responses, linking innate danger signaling and autoreactive antibody production within a single tissue site.

The adoptive transfer result is especially informative, because it separates the antibody itself from the cells that produce it. Accelerated plaque development following antibody delivery alone indicates that circulating anti-H2B immunoglobulin is sufficient to promote disease, pointing future mechanistic studies toward how the antibody engages antigens within the vessel wall and what effector pathways it recruits once bound.

Subject of Research: Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis

Article Title: Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis

Article References: Zhang, C., Zhang, X., Ran, Y., Wang, Z., Li, L., Wang, S., Zheng, J., Zhang, Y., Sun, T., Li, Y., Lu, S., Hong, M., Ma, Z., Steffens, S., Hristov, M., Blanchet, X., Zhu, J., Dou, X., Deng, X., … Yin, C. (2026). Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis. Nature Cardiovascular Research, 5(9), 869-890. https://doi.org/10.1038/s44161-026-00864-w

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00864-w

Keywords: Artery, tertiary, lymphoid, organs, encode, pathogenic, high-affinity, autoantibody, autoantigen, pair, atherosclerosis, scientific research

Neuromyelitis optica spectrum disorder has long been distinguished from multiple sclerosis by its serological signature. In 2004, Lennon and colleagues identified a serum autoantibody that marks the disease and separates it clearly from multiple sclerosis, an antibody directed against aquaporin-4, a water channel protein abundantly expressed on astrocytes at the blood-brain barrier and within the central nervous system parenchyma. The binding of these pathogenic immunoglobulin G antibodies to aquaporin-4 triggers complement activation, inflammatory injury to astrocytes, and secondary damage to neurons and oligodendrocytes. Because the antibody is produced by B lineage cells, the logical therapeutic strategy has been to deplete the cells that generate it.

That strategy has been validated repeatedly. Rituximab, a chimeric monoclonal antibody targeting CD20 on the surface of pre-B cells and mature B cells, entered clinical practice on the strength of open-label series and was later tested in the RIN-1 study, a multicentre, randomised, double-blind, placebo-controlled trial published in The Lancet Neurology in 2020, which established its safety and efficacy in the disorder. Inebilizumab, a humanized anti-CD19 antibody with a broader reach across the B cell lineage because it also targets plasma cell precursors, demonstrated benefit in the N-MOmentum phase 2/3 trial reported in The Lancet in 2019. Complement inhibition with eculizumab, reported in the New England Journal of Medicine in 2019, provided an alternative downstream approach by blocking the terminal complement pathway that the pathogenic antibodies engage.

Now obinutuzumab β, a glycoengineered type II anti-CD20 monoclonal antibody, has produced remarkable results in a phase 3 randomized controlled trial described by Wu and colleagues in Nature Medicine. Unlike type I anti-CD20 antibodies such as rituximab, type II antibodies like obinutuzumab engage CD20 in a manner that promotes direct cell death through non-apoptotic mechanisms and mediates more efficient depletion of certain B cell compartments, including tissue-resident populations that are less accessible to complement-dependent mechanisms. The glycoengineering of the Fc region enhances affinity for activating Fc gamma receptors on effector cells, sharpening antibody-dependent cellular cytotoxicity. These pharmacological distinctions matter, because the depth of depletion achieved within different B cell niches may determine how thoroughly autoantibody production is suppressed.

This is precisely the distinction Nakashima highlights in his analysis. The pathogenic anti-aquaporin-4 antibodies in neuromyelitis optica spectrum disorder are secreted by plasmablasts and plasma cells, differentiated descendants of B cells that express little or no surface CD20 and are therefore invisible to all anti-CD20 therapies. Yet clinical experience shows that depleting CD20-positive B cells nevertheless suppresses disease activity in most patients, implying that the continuously replenished pool of CD20-positive B cells is essential for sustaining the plasmablast population that secretes the pathogenic antibody. Fundamental work by Chihara and colleagues, published in the Proceedings of the National Academy of Sciences in 2011, showed that interleukin-6 signaling promotes anti-aquaporin-4 autoantibody production from plasmablasts, suggesting that the survival and differentiation of antibody-secreting cells depend on signals delivered by the surrounding B cell and immune milieu that anti-CD20 therapy disrupts.

The deeper-versus-broader framing also captures a paradox that clinicians have observed since the earliest rituximab era. Nakashima himself reported, in the Journal of Clinical Neuroscience in 2011, transient increases in anti-aquaporin-4 antibody titers following rituximab treatment, associated with elevated serum levels of BAFF, a B cell activating factor belonging to the tumour necrosis factor family. When B cells are depleted, BAFF levels rise because the cytokine is no longer consumed by its targets, and this surge can paradoxically promote the differentiation of surviving precursors towards antibody-secreting cells. Perumal and colleagues documented disease exacerbation after rituximab induction in a subset of patients, a phenomenon plausibly linked to these humoral dynamics. Any new depleting agent must therefore be evaluated not only for how deeply it depletes circulating B cells but also for how it perturbs the regulatory cytokine networks that govern reconstitution.

Dysregulated B cell differentiation towards antibody-secreting cells is now recognised as a hallmark of the disease, as Hoshino and colleagues described in the Journal of Neuroinflammation in 2022. In patients with neuromyelitis optica spectrum disorder, the balance between naïve B cells, memory compartments, and plasmablasts is shifted, with expanded populations of antibody-secreting cells circulating in the blood and correlating with disease activity. This pathobiology explains why broader depletion strategies, such as those targeting CD19 across a wider span of B cell differentiation including plasmablast precursors, and deeper depletion strategies, such as those using type II anti-CD20 antibodies with enhanced effector function, both hold mechanistic appeal. The phase III results with obinutuzumab β suggest that the depth and character of depletion may translate directly into clinical protection against relapse, the outcome that matters most in a disease where each attack can leave permanent, disabling neurological damage.

The clinical stakes of these distinctions are considerable. Neuromyelitis optica spectrum disorder disproportionately affects women and shows a striking predilection for populations in East Asia, and attacks of optic neuritis and transverse myelitis can cause irreversible blindness and paralysis. Since the identification of the aquaporin-4 antibody, a growing therapeutic armamentarium has emerged, encompassing B cell depletion, complement inhibition, and blockade of the interleukin-6 receptor, each intercepting the autoimmune cascade at a different point. The demonstration that obinutuzumab β achieves striking efficacy adds a potent new option, but it also invites head-to-head comparisons that have not yet been performed, leaving open the question of whether deeper depletion of conventional B cell compartments truly outperforms broader depletion that extends into the plasmablast lineage.

Longer-term considerations also come into focus as depleting therapies mature. Repeated courses of B cell depletion carry implications for humoral immunity, vaccine responses, and infection risk, and the dynamics of B cell reconstitution after obinutuzumab β, with its enhanced potency, may differ meaningfully from those seen after rituximab or inebilizumab. Monitoring strategies based on circulating CD19 and CD27-positive cell counts, serum BAFF levels, and anti-aquaporin-4 antibody titers may ultimately allow clinicians to individualise retreatment intervals, depleting deeply enough to prevent relapse while avoiding the prolonged immunosuppression that extended courses might otherwise impose. Biomarker-driven personalisation of this kind remains aspirational, but the mechanistic groundwork laid over the past two decades makes it increasingly plausible.

What the phase III obinutuzumab β trial ultimately delivers, in Nakashima’s assessment, is both a confirmation and a challenge. The confirmation is that B cell depletion remains the most reliable therapeutic principle yet discovered for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, capable of preventing the relapses that define the disease’s destructive course. The challenge is to move beyond the blunt question of whether B cells should be depleted and toward the precise one of which subpopulations sustain the autoimmune process, and how the depth, breadth, and timing of depletion can be tuned to maximize benefit while minimizing risk. As next-generation antibodies push the limits of what depletion can achieve, the field is converging on a richer, more granular understanding of B cell biology in neuroimmunological disease, one in which the architecture of the humoral immune response, rather than its mere suppression, becomes the true target of therapy.

Subject of Research: B cell depletion therapy for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder

Article Title: Deeper versus broader B cell depletion in neuromyelitis optica spectrum disorder

Article References: Nakashima, I. (2026). Deeper versus broader B cell depletion in neuromyelitis optica spectrum disorder. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01269-w

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01269-w

Keywords: neuromyelitis optica spectrum disorder, B cell depletion, obinutuzumab beta, aquaporin-4 antibody, anti-CD20 therapy, plasmablasts, rituximab, inebilizumab, neuroimmunology, phase III trial, BAFF, autoantibody